Pevesa Biotech, S.A.

Based in Spain, Pevesa Biotech, S. A. specializes in plant-based proteins and derivatives, focusing on providing innovative solutions for diverse industries including food, feed, cosmetics, and bioscience. Pevesa Biotech, S.

A. develops plant-based proteins and derivatives. Founded in 2005 in Sevilla, Spain, the company has undergone significant changes and was acquired by Kerry Group plc from Caixa Capital Risc and SuanFarma in February 2020, although financial terms remain undisclosed. The company primarily operates out of its headquarters in Sevilla.

Pevesa specializes in the development and production of plant-based proteins and derivatives, with a strong emphasis on pea and rice protein as well as hydrolysates. Their products cater to a wide array of industries, including food, feed, cosmetics, bioscience, and agro-science, utilizing advanced, solvent-free enzymatic technology for extraction to guarantee high-quality, natural ingredients. Pevesa’s offerings address customer needs in personal care and oral care, leveraging unique active components found in citrus fruits, and are distributed globally across North America, Europe, and Asia, serving both B2B and consumer markets. In 2023, Pevesa reported a revenue of EUR 15,140,135.

1, while its EBITDA for the same year was EUR -938,496. 2. The company generates revenue through direct B2B transactions with manufacturers and suppliers, potentially through partnerships and supply agreements that incorporate Pevesa's plant-based proteins into various product offerings. Following the acquisition by Kerry Group plc, Pevesa Biotech is expected to expand its product offerings and market reach.

Recent funding from the acquisition will likely support the development of new products and initiatives, although specific upcoming launches and timelines have not been disclosed. The focus will likely include enhancing their presence in existing markets and exploring opportunities in new geographic regions.